Andra AP fonden Increases Holdings in Stryker Corporation $SYK

Andra AP fonden lifted its holdings in Stryker Corporation (NYSE:SYK) by 30.2% in the first quarter, Holdings Channel reports. The fund owned 65,055 shares of the medical technology company’s stock after purchasing an additional 15,095 shares during the quarter. Andra AP fonden’s holdings in Stryker were worth $21,376,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in SYK. Godfrey Financial Associates Inc. purchased a new stake in Stryker during the 4th quarter valued at $26,000. Sankala Group LLC bought a new stake in Stryker in the fourth quarter worth $26,000. United Financial Planning Group LLC purchased a new position in Stryker during the third quarter worth $27,000. Atlas Capital Advisors Inc. purchased a new position in Stryker during the fourth quarter worth $27,000. Finally, DJE Kapital AG bought a new position in Stryker during the fourth quarter valued at $28,000. 77.09% of the stock is owned by institutional investors.

Insider Transactions at Stryker

In other news, VP Robert S. Fletcher sold 4,544 shares of the firm’s stock in a transaction that occurred on Thursday, May 28th. The shares were sold at an average price of $306.87, for a total transaction of $1,394,417.28. Following the transaction, the vice president directly owned 10,582 shares of the company’s stock, valued at approximately $3,247,298.34. This trade represents a 30.04% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Ronda E. Stryker sold 310,000 shares of the business’s stock in a transaction that occurred on Tuesday, May 26th. The shares were sold at an average price of $312.23, for a total value of $96,791,300.00. Following the completion of the sale, the director owned 1,924,880 shares of the company’s stock, valued at $601,005,282.40. The trade was a 13.87% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 323,264 shares of company stock valued at $100,659,489. 4.60% of the stock is currently owned by company insiders.

Stryker Stock Down 0.3%

NYSE:SYK opened at $318.80 on Tuesday. The company has a market cap of $122.22 billion, a price-to-earnings ratio of 36.90, a price-to-earnings-growth ratio of 2.05 and a beta of 0.77. Stryker Corporation has a twelve month low of $281.00 and a twelve month high of $404.87. The company has a current ratio of 2.11, a quick ratio of 1.25 and a debt-to-equity ratio of 0.62. The stock has a fifty day simple moving average of $313.41 and a 200-day simple moving average of $336.46.

Stryker (NYSE:SYK) last posted its quarterly earnings results on Thursday, April 30th. The medical technology company reported $2.60 EPS for the quarter, missing analysts’ consensus estimates of $2.98 by ($0.38). The company had revenue of $6.02 billion during the quarter, compared to the consensus estimate of $6.34 billion. Stryker had a return on equity of 23.42% and a net margin of 13.20%.The company’s revenue for the quarter was up 2.6% on a year-over-year basis. During the same quarter in the previous year, the company posted $2.84 earnings per share. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. Analysts anticipate that Stryker Corporation will post 14.99 EPS for the current year.

Stryker Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, July 31st. Shareholders of record on Tuesday, June 30th will be paid a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a yield of 1.1%. The ex-dividend date is Tuesday, June 30th. Stryker’s dividend payout ratio is currently 40.74%.

Wall Street Analysts Forecast Growth

Several brokerages have recently weighed in on SYK. Wells Fargo & Company reduced their target price on shares of Stryker from $456.00 to $418.00 and set an “overweight” rating on the stock in a research note on Friday, May 1st. The Goldman Sachs Group reiterated a “neutral” rating and set a $361.00 price target on shares of Stryker in a report on Friday, May 1st. BMO Capital Markets assumed coverage on shares of Stryker in a research report on Wednesday, July 8th. They issued an “outperform” rating and a $369.00 price objective on the stock. Barclays decreased their price objective on shares of Stryker from $469.00 to $394.00 and set an “overweight” rating for the company in a research note on Monday, May 4th. Finally, BTIG Research set a $371.00 target price on Stryker in a research report on Monday, July 13th. One investment analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and six have given a Hold rating to the company. According to data from MarketBeat.com, Stryker presently has an average rating of “Moderate Buy” and a consensus price target of $392.52.

About Stryker

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.